Drugs for Alzheimer’s disease provide modest symptomatic improvement in cognitive function and global clinical status but do not halt or reverse the underlying neurodegenerative process. Alzheimer’s disease is the most common cause of dementia, characterized by extracellular amyloid-beta plaque deposition and intracellular neurofibrillary tangles of hyperphosphorylated tau protein. Pharmacotherapy targets neurotransmitter deficits and, more recently, the underlying amyloid pathology.
What Is Alzheimer’s Disease Pharmacotherapy?
The cholinergic hypothesis of Alzheimer’s disease posits that degeneration of basal forebrain cholinergic neurons leads to a cortical acetylcholine deficit that contributes to cognitive decline. This provides the rationale for cholinesterase inhibitor therapy. Glutamatergic excitotoxicity is another therapeutic target. Emerging disease-modifying therapies aim to reduce amyloid burden, though their clinical benefit remains modest and access is limited.
Drug Classes and Mechanisms
Cholinesterase inhibitors include donepezil, rivastigmine, and galantamine. These agents inhibit acetylcholinesterase (and butyrylcholinesterase in the case of rivastigmine), increasing the concentration and duration of acetylcholine at central synapses. Donepezil is administered once daily and is generally well tolerated. Rivastigmine is available in oral and transdermal formulations, with the patch reducing gastrointestinal side effects. Galantamine also modulates nicotinic acetylcholine receptors. NMDA receptor antagonist memantine is an uncompetitive antagonist of the N-methyl-D-aspartate glutamate receptor, reducing pathological glutamatergic excitotoxicity while preserving physiological synaptic transmission. It is used in moderate to severe disease, either as monotherapy or in combination with cholinesterase inhibitors.
Therapeutic Uses
Cholinesterase inhibitors are indicated for mild to moderate Alzheimer’s dementia, while donepezil is also approved for severe disease. Memantine is indicated for moderate to severe Alzheimer’s disease. Combined therapy with a cholinesterase inhibitor and memantine provides modest additional benefit over either agent alone. The decision to initiate therapy requires careful discussion of expected benefits and side effect risks. Response is variable, and treatment should be discontinued if cognitive decline continues at an accelerated rate or if intolerable side effects occur.
Adverse Effects
Cholinesterase inhibitors commonly cause gastrointestinal side effects including nausea, vomiting, diarrhea, and anorexia, which can often be managed with dose titration and administration with food. Other side effects include bradycardia, syncope, muscle cramps, and insomnia. Memantine is generally well tolerated, with dizziness, headache, and constipation being the most common adverse effects. Both drug classes can cause confusion and agitation in some patients.
Key Clinical Considerations
The benefits of current pharmacotherapy are modest, typically delaying cognitive decline by 6 to 12 months on average. Therapy should be initiated early in the disease course for maximum benefit. Drug interactions are notable for cholinesterase inhibitors, which may potentiate the effects of succinylcholine and beta-blockers. The emergence of anti-amyloid monoclonal antibodies such as aducanumab and lecanemab represents a shift toward disease-modifying therapy, but their use requires careful patient selection based on amyloid PET confirmation, genetic testing for APOE4 status, and monitoring for amyloid-related imaging abnormalities.
Conclusion
Symptomatic pharmacotherapy with cholinesterase inhibitors and memantine remains the standard of care for Alzheimer’s disease. These agents provide meaningful but limited benefit for cognitive and functional outcomes. The advent of anti-amyloid immunotherapies offers a new treatment paradigm, though questions regarding efficacy, safety, and accessibility persist. Ongoing research into tau-directed therapies and neuroprotective strategies continues to evolve the landscape.
